以实用的三组分区域选择性合成类似药物的 3-芳基(或杂芳基)-5,6-二氢苯并[h]噌啉,作为潜在的非共价多靶点抑制剂防治神经退行性疾病。

IF 4.1 3区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY ACS Chemical Neuroscience Pub Date : 2024-04-22 DOI:10.1021/acschemneuro.4c00055
Hossein Mousavi*, Mehdi Rimaz and Behzad Zeynizadeh, 
{"title":"以实用的三组分区域选择性合成类似药物的 3-芳基(或杂芳基)-5,6-二氢苯并[h]噌啉,作为潜在的非共价多靶点抑制剂防治神经退行性疾病。","authors":"Hossein Mousavi*,&nbsp;Mehdi Rimaz and Behzad Zeynizadeh,&nbsp;","doi":"10.1021/acschemneuro.4c00055","DOIUrl":null,"url":null,"abstract":"<p >Neurodegenerative diseases (NDs) are one of the prominent health challenges facing contemporary society, and many efforts have been made to overcome and (or) control it. In this research paper, we described a practical one-pot two-step three-component reaction between 3,4-dihydronaphthalen-1(2<i>H</i>)-one (<b>1</b>), aryl(or heteroaryl)glyoxal monohydrates (<b>2a</b>–<b>h</b>), and hydrazine monohydrate (NH<sub>2</sub>NH<sub>2</sub>•H<sub>2</sub>O) for the regioselective preparation of some 3-aryl(or heteroaryl)-5,6-dihydrobenzo[<i>h</i>]cinnoline derivatives (<b>3a</b>–<b>h</b>). After synthesis and characterization of the mentioned cinnolines (<b>3a</b>–<b>h</b>), the <i>in silico</i> multi-targeting inhibitory properties of these heterocyclic scaffolds have been investigated upon various <i>Homo sapiens</i>-type enzymes, including <i>h</i>MAO-A, <i>h</i>MAO-B, <i>h</i>AChE, <i>h</i>BChE, <i>h</i>BACE-1, <i>h</i>BACE-2, <i>h</i>NQO-1, <i>h</i>NQO-2, <i>h</i>nNOS, <i>h</i>iNOS, <i>h</i>PARP-1, <i>h</i>PARP-2, <i>h</i>LRRK-2<sup>(G2019S)</sup>, <i>h</i>GSK-3β, <i>h</i>p38α MAPK, <i>h</i>JNK-3, <i>h</i>OGA, <i>h</i>NMDA receptor, <i>h</i>nSMase-2, <i>h</i>IDO-1, <i>h</i>COMT, <i>h</i>LIMK-1, <i>h</i>LIMK-2, <i>h</i>RIPK-1, <i>h</i>UCH-L1, <i>h</i>PARK-7, and <i>h</i>DHODH, which have confirmed their functions and roles in the neurodegenerative diseases (NDs), based on molecular docking studies, and the obtained results were compared with a wide range of approved drugs and well-known (with IC<sub>50</sub>, EC<sub>50</sub>, etc.) compounds. In addition, <i>in silico</i> ADMET prediction analysis was performed to examine the prospective drug properties of the synthesized heterocyclic compounds (<b>3a</b>–<b>h</b>). The obtained results from the molecular docking studies and ADMET-related data demonstrated that these series of 3-aryl(or heteroaryl)-5,6-dihydrobenzo[<i>h</i>]cinnolines (<b>3a</b>–<b>h</b>), especially hit ones, can really be turned into the potent core of new drugs for the treatment of neurodegenerative diseases (NDs), and/or due to the having some reactionable locations, they are able to have further organic reactions (such as cross-coupling reactions), and expansion of these compounds (for example, with using other types of aryl(or heteroaryl)glyoxal monohydrates) makes a new avenue for designing novel and efficient drugs for this purpose.</p>","PeriodicalId":13,"journal":{"name":"ACS Chemical Neuroscience","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Practical Three-Component Regioselective Synthesis of Drug-Like 3-Aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines as Potential Non-Covalent Multi-Targeting Inhibitors To Combat Neurodegenerative Diseases\",\"authors\":\"Hossein Mousavi*,&nbsp;Mehdi Rimaz and Behzad Zeynizadeh,&nbsp;\",\"doi\":\"10.1021/acschemneuro.4c00055\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Neurodegenerative diseases (NDs) are one of the prominent health challenges facing contemporary society, and many efforts have been made to overcome and (or) control it. In this research paper, we described a practical one-pot two-step three-component reaction between 3,4-dihydronaphthalen-1(2<i>H</i>)-one (<b>1</b>), aryl(or heteroaryl)glyoxal monohydrates (<b>2a</b>–<b>h</b>), and hydrazine monohydrate (NH<sub>2</sub>NH<sub>2</sub>•H<sub>2</sub>O) for the regioselective preparation of some 3-aryl(or heteroaryl)-5,6-dihydrobenzo[<i>h</i>]cinnoline derivatives (<b>3a</b>–<b>h</b>). After synthesis and characterization of the mentioned cinnolines (<b>3a</b>–<b>h</b>), the <i>in silico</i> multi-targeting inhibitory properties of these heterocyclic scaffolds have been investigated upon various <i>Homo sapiens</i>-type enzymes, including <i>h</i>MAO-A, <i>h</i>MAO-B, <i>h</i>AChE, <i>h</i>BChE, <i>h</i>BACE-1, <i>h</i>BACE-2, <i>h</i>NQO-1, <i>h</i>NQO-2, <i>h</i>nNOS, <i>h</i>iNOS, <i>h</i>PARP-1, <i>h</i>PARP-2, <i>h</i>LRRK-2<sup>(G2019S)</sup>, <i>h</i>GSK-3β, <i>h</i>p38α MAPK, <i>h</i>JNK-3, <i>h</i>OGA, <i>h</i>NMDA receptor, <i>h</i>nSMase-2, <i>h</i>IDO-1, <i>h</i>COMT, <i>h</i>LIMK-1, <i>h</i>LIMK-2, <i>h</i>RIPK-1, <i>h</i>UCH-L1, <i>h</i>PARK-7, and <i>h</i>DHODH, which have confirmed their functions and roles in the neurodegenerative diseases (NDs), based on molecular docking studies, and the obtained results were compared with a wide range of approved drugs and well-known (with IC<sub>50</sub>, EC<sub>50</sub>, etc.) compounds. In addition, <i>in silico</i> ADMET prediction analysis was performed to examine the prospective drug properties of the synthesized heterocyclic compounds (<b>3a</b>–<b>h</b>). The obtained results from the molecular docking studies and ADMET-related data demonstrated that these series of 3-aryl(or heteroaryl)-5,6-dihydrobenzo[<i>h</i>]cinnolines (<b>3a</b>–<b>h</b>), especially hit ones, can really be turned into the potent core of new drugs for the treatment of neurodegenerative diseases (NDs), and/or due to the having some reactionable locations, they are able to have further organic reactions (such as cross-coupling reactions), and expansion of these compounds (for example, with using other types of aryl(or heteroaryl)glyoxal monohydrates) makes a new avenue for designing novel and efficient drugs for this purpose.</p>\",\"PeriodicalId\":13,\"journal\":{\"name\":\"ACS Chemical Neuroscience\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Chemical Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acschemneuro.4c00055\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Chemical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acschemneuro.4c00055","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

神经退行性疾病(NDs)是当代社会面临的突出健康挑战之一,人们一直在努力克服和(或)控制这种疾病。在这篇研究论文中,我们介绍了一种实用的一锅两步三组分反应,即 3,4-二氢萘-1(2H)-酮 (1)、芳基(或杂芳基)乙二醛一水合物 (2a-h) 和肼一水合物 (NH2NH2-H2O),用于区域选择性地制备一些 3-芳基(或杂芳基)-5,6-二氢苯并[h]噌啉衍生物 (3a-h)。在合成和表征了上述噌啉衍生物(3a-h)之后,研究人员对这些杂环支架的多靶点抑制特性进行了研究、包括 hMAO-A、hMAO-B、hAChE、hBChE、hBACE-1、hBACE-2、hNQO-1、hNQO-2、hnNOS、hiNOS、hPARP-1、hPARP-2、hLRRK-2(G2019S)、hGSK-3β、hp38α MAPK、hJNK-3、hOGA、hNMDA 受体、hnSMase-2、hIDO-1、hCOMT、hLIMK-1、hLIMK-2、hRIPK-1、hUCH-L1、hPARK-7 和 hDHODH,这些研究证实了它们在神经退行性疾病(NDs)中的功能和作用。等)化合物进行比较。此外,还对合成的杂环化合物(3a-h)的药物性质进行了硅学 ADMET 预测分析。分子对接研究和 ADMET 相关数据的结果表明,这些 3-芳基(或杂芳基)-5,6-二氢苯并[h]噌啉(3a-h)系列,尤其是其中的热门化合物,确实可以成为治疗神经退行性疾病(NDs)新药的有效核心、这些化合物的扩展(例如使用其他类型的芳基(或杂芳基)乙二醛一水合物)为设计新型高效药物提供了新的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Practical Three-Component Regioselective Synthesis of Drug-Like 3-Aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines as Potential Non-Covalent Multi-Targeting Inhibitors To Combat Neurodegenerative Diseases

Neurodegenerative diseases (NDs) are one of the prominent health challenges facing contemporary society, and many efforts have been made to overcome and (or) control it. In this research paper, we described a practical one-pot two-step three-component reaction between 3,4-dihydronaphthalen-1(2H)-one (1), aryl(or heteroaryl)glyoxal monohydrates (2ah), and hydrazine monohydrate (NH2NH2•H2O) for the regioselective preparation of some 3-aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnoline derivatives (3ah). After synthesis and characterization of the mentioned cinnolines (3ah), the in silico multi-targeting inhibitory properties of these heterocyclic scaffolds have been investigated upon various Homo sapiens-type enzymes, including hMAO-A, hMAO-B, hAChE, hBChE, hBACE-1, hBACE-2, hNQO-1, hNQO-2, hnNOS, hiNOS, hPARP-1, hPARP-2, hLRRK-2(G2019S), hGSK-3β, hp38α MAPK, hJNK-3, hOGA, hNMDA receptor, hnSMase-2, hIDO-1, hCOMT, hLIMK-1, hLIMK-2, hRIPK-1, hUCH-L1, hPARK-7, and hDHODH, which have confirmed their functions and roles in the neurodegenerative diseases (NDs), based on molecular docking studies, and the obtained results were compared with a wide range of approved drugs and well-known (with IC50, EC50, etc.) compounds. In addition, in silico ADMET prediction analysis was performed to examine the prospective drug properties of the synthesized heterocyclic compounds (3ah). The obtained results from the molecular docking studies and ADMET-related data demonstrated that these series of 3-aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines (3ah), especially hit ones, can really be turned into the potent core of new drugs for the treatment of neurodegenerative diseases (NDs), and/or due to the having some reactionable locations, they are able to have further organic reactions (such as cross-coupling reactions), and expansion of these compounds (for example, with using other types of aryl(or heteroaryl)glyoxal monohydrates) makes a new avenue for designing novel and efficient drugs for this purpose.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ACS Chemical Neuroscience
ACS Chemical Neuroscience BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
9.20
自引率
4.00%
发文量
323
审稿时长
1 months
期刊介绍: ACS Chemical Neuroscience publishes high-quality research articles and reviews that showcase chemical, quantitative biological, biophysical and bioengineering approaches to the understanding of the nervous system and to the development of new treatments for neurological disorders. Research in the journal focuses on aspects of chemical neurobiology and bio-neurochemistry such as the following: Neurotransmitters and receptors Neuropharmaceuticals and therapeutics Neural development—Plasticity, and degeneration Chemical, physical, and computational methods in neuroscience Neuronal diseases—basis, detection, and treatment Mechanism of aging, learning, memory and behavior Pain and sensory processing Neurotoxins Neuroscience-inspired bioengineering Development of methods in chemical neurobiology Neuroimaging agents and technologies Animal models for central nervous system diseases Behavioral research
期刊最新文献
Discovering Effective Chiral Dipeptides against Aβ(1-42) Aggregation by the Computational Screening Strategy. Multicolorimetric Sensor Array Based on Silver Metallization of Gold Nanorods for Discriminating Dopaminergic Agents. Alzheimer's Disease Immunotherapy and Mimetic Peptide Design for Drug Development: Mutation Screening, Molecular Dynamics, and a Quantum Biochemistry Approach Focusing on Aducanumab::Aβ2-7 Binding Affinity. Light-Activatable, Cell-Type Specific Labeling of the Nascent Proteome. Selective, Intrinsically Fluorescent Trk Modulating Probes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1